ONZETRA Xsail
Acute Treatment of Migraine
ApprovedActive
Key Facts
About Currax Pharmaceuticals
Currax Pharmaceuticals is a commercial-stage biopharma company that has built a portfolio of marketed products, most notably the obesity drug CONTRAVE®. The company leverages a business model of acquiring and commercializing established or niche pharmaceutical products, with a significant strategic focus on the obesity treatment market. Under CEO George Hampton, Currax emphasizes direct-to-patient platforms, educational campaigns, and ensuring supply chain resilience to compete in the dynamic chronic disease landscape.
View full company profileOther Acute Treatment of Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| Elismetrep (K-304) | Kallyope | Phase 2 |
| RizaFilm® (RizaPort®) | Gensco Pharma | Approved/Pre-launch |
| TREXIMET | Currax Pharmaceuticals | Approved |
| Nerivio | Theranica | Approved |
| NVI-100 | Nuvie Bio | Phase 1 |
| gammaCore | electroCore | Commercial |